SLS SELLAS Life Sciences Group Inc

$SLS Thank you guys for all the love and support during one of the more harrowing 24 hour periods I’ve experienced. Feels good to get through the margin call and live to fight another day. Maybe I’ll have time to recoup some of the lost shares by switching brokers, but if Sterg drops the data PR before I am able, well then I am perfectly ok with the parabolic send. Thank you all again for talking me through that. We battle again on Monday💪🏻🙏🏻

$SLS Crazy how retards repost other retards so even when I block retards I have to hear their retarded ideas.

$SLS why do I get the feeling that this is our last truly crappy week being invested in this stock?

$SLS putting the CEOs comments (as well as anyone on any of the boards) comments aside. We all have one thing in common. We are blinded. I can’t help but put my faith in the most relevant source. The kol’s are the only source that could see the data when they met to review. It is something seeing their optimism of GPS (in their words) potentially becoming the new standard of care. That is powerful verbiage for some top oncology physicians. If you haven’t reviewed what the kol’s had to say, do yourself a favor to take a look and review. It is worth your time.

$SLS With 126 total patients randomized and 80 confirmed deaths, ~ 46 patients remain alive across the entire study. If the GPS peptide immunotherapy has successfully flattened the survival curve into a long-term plateau, the vast majority of those remaining 46 survivors are sitting on the treatment side of the ledger. When you anchor a clinical trial in the true biological constraints of human leukemia (a 6–8 month real-world BAT ceiling), a sub-0.30 Hazard Ratio becomes a highly viable home run scenario.

$SLS Why FDA and Institutional Review Boards approved a protocol amendment changing the dosing rules for GPS from a fixed, time-limited schedule to continuous, "infinite dosing" until relapse. • As the trial progressed, Key Opinion Leaders argued it was ethically wrong to cut off a therapeutic vaccine that was successfully training the immune system to suppress leukemia relapse. • They requested protocol modifications to allow patients to receive continued booster doses into their second, third, and now fourth years to keep the immune response actively locked onto the WT1 target. This rule change heavily underpins the bullish "long-tail" thesis. The only group eligible to receive continuous, multi-year dosing under this amendment is the GPS arm when the BAT control arm does not receive GPS. The fact that patients are documented as being actively dosed into their 3rd and 4th years heavily implies that the vaccine is achieving exactly what it was designed to do.

$SLS NFA GLTAL I’m starting to believe that the TIMING of SELLAS’s 80th-event announcement may be a huge clue that REGAL has already succeeded. Three things stand out: 1. For the first time, SELLAS did not disclose the exact reporting date of the 80th event. Why? 2. SELLAS announced the “80th” milestone just 18 hours before ASH’s late-breaking abstract (LBA) deadline. Why that exact day? 3. Here’s the critical connection: ASH’s embargo begins upon submission, with a special exception for LIMITED TOPLINE DATA, not routine milestone announcements. SELLAS had promised to announce the 80th event, so it needed to PR the milestone BEFORE a potential LBA submission to avoid an embargo conflict. Now the really important part: ASH requires substantive clinical results for an LBA. You cannot submit REGAL’s final Phase 3 efficacy findings without at least having topline OS results, including the treatment effect and statistical significance. A theory: The 80th death occurred earlier, SELLAS already had topline results, and October 28 was deliberately chosen to announce the “80th” milestone before submitting REGAL to ASH. why would management submit a failed Phase 3 trial for one of ASH’s extremely selective late-breaking presentation slots?

$SLS Short sales the previous 2 days are 72% and 60% of daily volume. This isn't some kind of sell the news BS people love to post. I'm glad the science outweighs anything someone spouts here. The IDMC correctly predicted the 60th event because they knew the data and could reasonably predict because BAT hasn't changed. In October 2025 2 doctors that see AML patients BOTH reiterated the 8 month expectations for BAT survival. Those doctors also stated their belief that GPS would exceed 30 months. No matter what any clown poster says on ST, the doctors and the IDMC are the most reliable providers of factual data.

$SLS This role at IQVIA was identified by another shareholder yesterday. It's posted across 8 Cities on the IQVIA careers page. The FIT is THERE. These roles help carry the Sellas Assets into the Medical Community on behalf of BIG BP.. and the transition out of Sellas into New OWNER. "Join a Team Advancing Innovation in Hematologic Malignancies - Hematology/Oncology Medical Science Liaison IQVIA is seeking experienced Medical Science Liaisons (MSLs) to support a late-stage clinical development program in Acute Myeloid Leukemia (AML). This role provides the opportunity to engage with investigators, hematologists, oncologists, and other healthcare professionals at the forefront of AML research and patient care."

$SLS I don't see how REGAL can fail. Regarding BAT, we all know Venetoclax ain't it (it provides the best results of all the allowed BAT in REGAL, which is around seven months mOS), and receiving stem cell was a disqualifying act in REGAL. Some patients have been on GPS in REGAL since February 2021 (approaching six years!). It's highly likely that the vast majority of the <=47 patients still alive today are on GPS. There isn't much more to say. The big guys are just taking the little guys' money at this point. But I am quite impressed with the little guys' resilience in this stock. We'll see how it holds in the coming weeks. GLTA longs!!!

$SLS Unprecedented survival, IQVIA hiring for bring to market a Stage 3 AML drug, Giant booth for AML conference you don't buy unless you're announcing something big, consistent corporate messaging and structuring for buyout. What else?

$SLS Yawn! Us longs just carry on picking up ”cheap shares” and wait for the results. Nothing has changed just the usual panic sale from newbies.

$SLS I am going to zone out over the weekend, and take some holiday, in the Belgian Ardenne forest. For those who know… you know that means some of the finest Belgian beers (Trappist). Currently enjoying a La Chouffe ! A leprechaun (🫣😏) told me we are close to the golden pot ! I have even seen a rainbow 🌈 All smoke and mirrors till the unblinding. And don’t forget… we had R&D day, with Dr. Tsirigotis, almost a year ago… they were convinced of GPS when he spoke. No reason to think otherwise. Have a great weekend and Halloween my fellow bulls 🎃

$SLS Admittedly, a lot of us have been riding an increasingly high amplitude emotional wave as of late especially since the 80th. Although of no consequence to us long term investors, in for the duration, a $10 or above close would sure help alleviate some of the anxiety that comes with the ‘troughs’. Of course that’s the exact reason we should not expect it. Let’s always be mindful of the corrosive effects that emotions have on investing. I know these posts offer little value except to highlight the fact that ‘you’ are not alone out there and that in itself can be reassuring at times. GLTA.

$SLS Well, I’m buying as many SLS shares as I can afford at these levels. I haven’t borrowed money or taken on any other financial liabilities. I have food, a good life—but every single penny I can spare goes into SLS shares. Why? 🤔 That’s a stupid question, I am 76 yo and do what I do with sense 😎🏖💪👊

$SLS I have watched just about every trade cross on level 2 since the 80th announced. Also on another screen, the options trades. We are in for some fun times folks.

$SLS  Anybody here who does not believe that some of the big Pharma can shell out tens of billions, when so desired, is out of touch with the kind of market caps they sport. Take Eli Lilly: up 3% on a $3.1 trillion market cap. 90 billion in a single trading day. Half of that = 45 billion. That’s close to where many of us believe SLS will be priced in a buyout. The Point: really small potatoes for some big Pharma, for medications that may extend life of cancer patients indefinitely, and we know how BP loves that category/characteristic!

$SLS On a positive thing that has happened in the last 48hrs is the shorts have probably shredded 20% of their positions. I would not be surprised if the short position went from 53M to below 42M. Hopefully we get an 009 update end of next week. Also be on the lookout for 13F/G in the next week for funds taking over 4.9% ownership. I can not believe we are in November on Sunday. To end on a super positive note we have been waiting for the 80th event for almost a year. The wait is now weeks away for data release. We are now officially in the end zone! Have a great weekend longs!

$SLS anyone that refers to themselves as ‘The Legendary Mayor’ has got to be a total fucking douche bag

$SLS Previous years Sellas just brought a poster. This year they found the need for a 20ft x 30ft room at ASH. Think about that longs.